Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing

  title={Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing},
  author={Bridget Myers and Vidhatha Reddy and Stephanie Chan and Quinn Thibodeaux and Nicholas D. Brownstone and John Koo},
  journal={Journal of Dermatological Treatment},
  pages={87 - 93}
Abstract Doxepin, a tricyclic antidepressant, is the most efficacious antipruritic available to dermatologists; however its use is often suboptimal because of significant interindividual variability in doxepin plasma levels and clinical response between patients taking the same dose. As result, the Food and Drug Administration approves a maximum dose of 300 mg of doxepin per day and a 10 mg per cc liquid doxepin concentrate. These allow patients to significantly increase or decrease their dose… 



Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Following the new guidelines for therapeutic drug monitoring in psychiatry holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.

Doxepin Plasma Concentrations: Is There Really a Therapeutic Range?

A methodologically sound study to determine a therapeutic range is required for the rational monitoring of doxepin and a preliminary working range of 50 to 250 ng/mL is proposed on the basis of critical reassessment of published data.

Therapeutic Drug Monitoring of Antidepressants

There are data to suggest that TDM can favourably affect the outcome of antidepressant treatment by providing a rational alternative to the inherently slower, trial and error practice of dosage titration based on clinical response.

Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions

Cautious dosing is advisable and TDM should be performed if a combination of valproic acid with doxepin or venlafaxine is administered, and a significant correlation between valProic acid serum level and dose-corrected doXepin+N-doxepin serum level is found.

Doxepin in the management of pruritus associated with allergic cutaneous reactions.

It appears that low-dose doxepin (10 mg po tid) is a potentially effective and well-tolerated alternative in patients who do not respond to conventional antihistamines and may be best suited to conditions involving intact skin that do not require application to large areas of the body, thereby reducing systemic absorption and adverse effects.

Efficacy of doxepin in the treatment of chronic idiopathic urticaria.

Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach

The analysis indicates that the factors age and, to some extent, body weight may be a guidance for individual doxepine dose regimens, which however needs confirmation in prospective clinical trials linking pharmacokinetics and therapeutic effect.

Low-dose doxepin for treatment of pruritus in patients on hemodialysis.

It is suggested that doxepin, a tricyclic antidepressant with anti-H1 receptor effect, can help improve pruritus resistant to antihistamines in end-stage renal disease patients who undergo hemodialysis.

Detection of doxepin and its major metabolite desmethyldoxepin in hair following drug therapy.

Hair samples collected from a patient receiving 25 mg of doxepin daily were analyzed and found the drug and its metabolite were still present in the patient's hair five months after the patient had stopped using the drug.

Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse.

It is suggested that patients should not qualify as nonresponders unless it can be demonstrated (and it is clinically applicable) that the steady-state serum TCA levels are stable within the upper limit of the recommended therapeutic range and serum level.